CMAB vs IMAB in Metastatic Prostate Cancer
Phase 4
Withdrawn
- Conditions
- Metastatic Prostate Cancer
- Registration Number
- NCT00255268
- Lead Sponsor
- AstraZeneca
- Brief Summary
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
- Histological diagnosis of D2 of Adenocarcinoma,
- Naivety to treatment
- Valuable bone metastasis
Exclusion Criteria
- Hematological, liver or renal toxicity Grade IV
- Severe and active infections
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method Quality of Life Safety
Trial Locations
- Locations (1)
Research Site
🇲🇽Mexico City, Mexico